Sign in
Taking peopleNo phase

Non-invasive Ultrasound and Hematoma Clearance After Intracerebral Hemorrhage

Key facts

Who runs it
Beijing Tiantan Hospital
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
86 people, planned
Started
12 Dec 2025
Expected to end
31 Dec 2027
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • non-invasive ultrasonic scalpel
  • Sham Comparator
Record updated
17 April 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Age 18 to 80 years
  • Spontaneous intracerebral hemorrhage (ICH)
  • Supratentorial ICH
  • Hematoma volume <30 mL (calculated using the ABC/2 method)
  • Glasgow Coma Scale (GCS) score >9 at randomization
  • Time from onset to randomization: 48-72 hours
  • Patient and/or legal representative provides informed consent

Who cannot take part

  • Patients scheduled for surgical intervention (including, but not limited to, hematoma evacuation [minimally invasive or conventional], decompressive craniectomy, hematoma aspiration, or external ventricular drainage) prior to the first dose of study treatment
  • Intracerebral hemorrhage attributed to other causes (e.g., cerebral aneurysm, cerebrovascular malformation, brain tumor, cerebral venous sinus thrombosis, hemorrhagic transformation of ischemic stroke, head trauma, anticoagulation therapy, hematologic disorders)
  • Hemorrhage located in the infratentorial region
  • Hemorrhage confined primarily to the ventricular system
  • Severe cardiac dysfunction (NYHA Class III or IV)
  • High-risk chronic arrhythmias (e.g., sick sinus syndrome, second- or third-degree atrioventricular block, bradycardia-related syncope without pacemaker implantation)
  • History of severe asthma or chronic obstructive pulmonary disease (COPD)
  • History of coagulopathy or systemic bleeding disorder
  • Pre-stroke modified Rankin Scale (mRS) score >2
  • Presence of other severe disease resulting in a life expectancy of less than 1 year
  • Inability to understand the study procedures and/or complete follow-up due to psychiatric illness, cognitive impairment, or emotional disorders
  • Severe hepatic impairment defined as ALT >2x ULN or AST >2x ULN (ULN = Upper Limit of Normal)
  • Severe renal impairment defined as serum creatinine >1.5x ULN
  • Leukopenia (<2 × 10⁹/L) or thrombocytopenia (<100 × 10⁹/L)
  • Clinical signs or symptoms suggestive of brain herniation (e.g., progressive decline in level of consciousness, diminished or absent pupillary light reflexes, bilateral pyramidal signs)
  • Women who are pregnant or lactating
  • Participation in another clinical trial within the past 3 months or current participation in another clinical trial

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Intracerebral hemorrhage (ICH) is one of the stroke subtypes with the highest global rates of disability and mortality, accounting for 15%-20% of all strokes. Currently, there is a lack of evidence-based interventions for ICH, with treatment primarily relying on supportive care. There is an urgent clinical need to explore new strategies and technologies. The investigators hypothesize that for ICH patients, best medical treatment combined with a non-invasive ultrasonic scalpel (ultrasound Doppler flow analyzer) may be superior to best medical treatment alone. The primary objective of this study is to determine the safety and efficacy of the non-invasive ultrasonic scalpel in promoting hematoma clearance in ICH patients.

The 2 groups in the trial

  • Ultrasound Intervention GroupTreatment being tested

    On the basis of best medical management, 2 MHz non-invasive ultrasonic scalpel was used for intervention within 48-72 hours after the occurrence of intracerebral hemorrhage, 20min/ day, and continued for 7 days.

    Treatment: non-invasive ultrasonic scalpel

  • Sham ComparatorSham treatment, for comparison

    On the basis of best medical management, a sham non-invasive ultrasonic scalpel (simulating real treatment with zero energy output) was applied within 48-72 hours after the occurrence of intracerebral hemorrhage, 20 min/day for 7 consecutive days

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Study on the Safety and Efficacy of Non-Invasive Transcranial Doppler Ultrasound in Promoting Hematoma Clearance for Intracerebral Hemorrhage
Criteria questions
Built from NCT07246473, who can take part
Record updated
17 April 2026